# CHEMBIOCHEM

DOI: 10.1002/cbic.201200279



### Targeting Tumour Proliferation with a Small-Molecule Inhibitor of AICAR Transformylase Homodimerization

Ian B. Spurr,<sup>[a]</sup> Charles N. Birts,<sup>[b]</sup> Francesco Cuda,<sup>[a]</sup> Stephen J. Benkovic,<sup>[c]</sup> Jeremy P. Blaydes,<sup>[b]</sup> and Ali Tavassoli<sup>\*[a, b]</sup>

Aminoimidazole carboxamide ribonucleotide transformylase/ inosine monophosphate cyclohydrolase (ATIC) is a bifunctional homodimeric enzyme that catalyzes the last two steps of de novo purine biosynthesis. Homodimerization of ATIC, a protein-protein interaction with an interface of over 5000 Å<sup>2</sup>, is required for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity, with the active sites forming at the interface of the interacting proteins. Here, we report the development of a small-molecule inhibitor of AICAR transformylase that functions by preventing the homodimerization of ATIC. The compound is derived from a previously reported cyclic hexapeptide inhibitor of AICAR transformylase (with a  $K_i$ of 17 µM), identified by high-throughput screening. The active motif of the cyclic peptide is identified as an arginine-tyrosine dipeptide, a capped analogue of which inhibits AlCAR transformylase with a  $K_i$  value of 84  $\mu$ M. A library of nonnatural analogues of this dipeptide was designed, synthesized, and assayed. The most potent compound inhibits AlCAR transformylase with a  $K_i$  value of 685 nM, a 25-fold improvement in activity from the parent cyclic peptide. The potential for this AlCAR transformylase inhibitor in cancer therapy was assessed by studying its effect on the proliferation of a model breast cancer cell line. Using a nonradioactive proliferation assay and live cell imaging, a dose-dependent reduction in cell numbers and cell division rates was observed in cells treated with our ATIC dimerization inhibitor.

### Introduction

The activity of many enzymes is controlled by their quaternary structure, through active sites that form at the interface of homodimeric or oligomeric complexes. These enzymes may not only be targeted with substrate analogues, but also by proteinprotein interaction inhibitors, enabling an alternative approach



Scheme 1. The final two steps of the de novo purine biosynthesis pathway catalyzed by ATIC.

to modulating their activity.<sup>[1]</sup> One such enzyme is aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC), a bifunctional, highly conserved, homodimer that catalyzes the last two steps of de novo purine biosynthesis (Scheme 1).<sup>[2]</sup> Structural studies have shown the ATIC homodimer to have two distinct domains, and a relatively large protein-protein interaction interface of over 5000 Å<sup>2,[3]</sup> The C-terminal aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase) domain catalyzes the transfer of a formyl group from N10-formyl-tetrahydrofolate (10-f-THF) to aminoimidazole carboxamide ribonucleotide (AICAR), and the N-terminal inosine monophosphate cyclohydrolase (IMPCH) domain catalyzes the subsequent dehydrative ring closure to give inosine monophosphate (IMP). The AICAR Tfase active sites are formed at the interface of two interacting ATIC molecules, with each monomer contributing residues to the folate and AICAR binding pockets.<sup>[3]</sup> Homodimerization is therefore a requisite for the AICAR Tfase activity of ATIC, but not for its IMPCH activity. The significant reliance of rapidly

dividing cells on de novo purine biosynthesis for nucleotide production<sup>[4]</sup> has resulted in much interest and effort towards the development of inhibitors of this enzyme and pathway for use as potential antineoplastic agents.<sup>[5]</sup>

ATIC inhibition has also been recently demonstrated to indirectly inhibit cell proliferation and cell cycle progression in

 [a] Dr. I. B. Spurr,<sup>+</sup> Dr. F. Cuda, Dr. A. Tavassoli School of Chemistry, University of Southampton Southampton, SO17 1BJ (UK) E-mail: a.tavassoli@soton.ac.uk

- [b] Dr. C. N. Birts,<sup>+</sup> Dr. J. P. Blaydes, Dr. A. Tavassoli Faculty of Medicine, University of Southampton Southampton SO16 6YD (UK)
- [c] Prof. S. J. Benkovic Department of Chemistry, Pennsylvania State University University Park, PA 16802 (USA)
- [<sup>+</sup>] These authors contributed equally to this work.
- Supporting information for this article is available on the WWW under
- http://dx.doi.org/10.1002/cbic.201200279.

human carcinomas by indirectly activating the AMP activated protein kinase (AMPK), highlighting the potential significance of ATIC inhibitors for use in cancer therapy.<sup>[6]</sup> The development of substrate and cofactor analogues that specifically inhibit ATIC activity has proven challenging however, with folatebased compounds displaying nonspecific activity and undesirable side effects.<sup>[7]</sup> The dimerization requisite for AICAR Tfase activity provides a mechanism by which ATIC may be selectively targeted in the presence of other folate-utilizing enzymes.<sup>[8]</sup> To this end, we previously reported the screening of a library of 3.2 million cyclic hexapeptides<sup>[9]</sup> for inhibitors of ATIC homodimerization.<sup>[8a]</sup> The most potent inhibitor identified was the cyclic peptide CRYFNV (1), which inhibits AICAR Tfase activity with a  $K_i$  value of  $17 \pm 4 \,\mu\text{M}$  by preventing ATIC homodimerization.<sup>[8a]</sup> Although a relatively modest inhibitor for direct use as a therapeutic, a six-membered cyclic peptide that blocks the interaction of the ATIC homodimer holds much potential for further development and evolution into a more potent small molecule.

#### **Results and Discussion**

#### Identification of the active motif of cyclo-CRYFNV

ered a laborious and time-consuming process.<sup>[10]</sup> Compared to its linear counterpart, a cyclic hexapeptide has limited conformational freedom, with substantially fewer possible structures. This conformational restriction, combined with the sequence homology observed in the nine selected ATIC inhibitors,<sup>[8a]</sup> indicated that some residues of the cyclic peptide ATIC inhibitor are key to its potency, with others simply functioning as a back-

placed with alanine.

Each alanine-scanning analogue was assayed for inhibition of the AICAR Tfase activity of ATIC. The initially ordered binding of 10-f-THF and AICAR to ATIC<sup>[11]</sup> result in a dimerization inhibitor effectively acting as a competitive inhibitor with respect to 10-f-THF, and a noncompetitive inhibitor with respect to AICAR;<sup>[8a]</sup> we therefore used Michaelis-Menten kinetics to

assess the potency of each analogue.

The development of small molecules from peptides is consid-

bone. To validate this hypothesis and identify the critical motif, we synthesized six analogues of cyclo-CRYFNV, in which each amino acid was sequentially re-



that the RY motif of cyclo-CRYFNV is responsible for its AICAR Tfase activity. The fivefold loss in activity may be attributed to the increase in conformational freedom of the active motif upon removal of the cyclic backbone; linear-CRYFNV inhibits AICAR Tfase with a  $K_i$  value of  $142 \pm 22 \,\mu M_i^{[8a]}$  an eightfold loss compared to the cyclic counterpart, due to the same reason.

The data (Table 1) indicated that the neighboring arginine and tyrosine residues are critical for the activity of cyclo-CRYFNV, as replacing either residue resulted in an inactive ATIC inhibitor. In contrast, replacing the other residues (FNVC) with alanine resulted in 2- to 40-fold loss of activity, suggesting that these amino acids are less critical for inhibitor activity, possibly

1629 www.chembiochem.org ChemBioChem 2012, 13, 1628 - 1634 © 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

Table 1. AICAR Tfase inhibition by CRYFNV alanine-scanning analogues.			
Compound	Sequence	<i>К</i> <sub>і</sub> [µм]	
1	cyclo-CRYFNV	17±3	
2	cyclo-ARYFNV	$651\pm25$	
3	cyclo-CAYFNV	> 2.5	
4	cyclo-CRAFNV	> 2.5	
5	cyclo-CRYANV	$38\pm 5$	
6	cyclo-CRYFAV	$368\pm29$	
7	cyclo-CRYFNA	$252\pm22$	

acting as a backbone to present the RY motif to ATIC. A truncated analogue of cyclo-CRYFNV, in which the FNVC backbone had been removed, was therefore designed (compound 8, Scheme 2), synthesized (Scheme 3) and assayed (Table 2) for its ability to inhibit AICAR Tfase.

The capped RY dimer 8 was found to inhibit the AICAR Tfase activity of ATIC with a  $K_i$  value of  $84 \pm 7 \mu M$ , suggesting



Scheme 2. The capped RY dipeptide 8 was designed to mimic the active RY motif (highlighted) of CRYFNV 1. RY analogues 9-17 containing unnatural amino acids were synthesized in an attempt to improve inhibitor activity.



# **CHEMBIO**CHEM

Table 2.      AICAR Tfase inhibition by RY analogues.				
Compound	$R^1$	R <sup>2</sup>	<i>К</i> <sub>i</sub> [µм]	
8	Н	OH	84±7	
9	Н	Н	$339\pm37$	
10	Н	F	$135\pm12$	
11	Н	OMe	87±9	
12	Н	CN	$56\pm5$	
13	Н	B(OH) <sub>2</sub>	$59\pm5$	
14	н	NO <sub>2</sub>	$0.685 \pm 0.035$	
15 <sup>[a]</sup>	Н	NO <sub>2</sub>	$52\pm4$	
16	Me	OH	$145\pm14$	
17	Me	NO <sub>2</sub>	$2.5\pm0.2$	

### Improving the activity of the RY dipeptide with unnatural amino acids

To improve the activity of the capped RY dimer 8, chemical spaces not accessible to our original cyclic peptide library (which is synthesized in vivo using split inteins<sup>[9,12]</sup> and therefore limited to the 20 canonical amino acids) were explored using unnatural amino acids. A series of related compounds containing electron-donating or electron-withdrawing parasubstituted tyrosine analogues were synthesized (9-14) to probe the electronic and steric requirements of the tyrosinebinding pocket. These compounds were assayed for AICAR Tfase inhibition (Table 2). Removing the hydroxyl group of tyrosine (compound 9) resulted in a fourfold loss of activity. Replacing the hydroxyl group with fluorine (compound 10) also resulted in activity loss (1.6-fold), while the p-methoxy derivative (compound 11) had similar levels of activity as the RY dimer. Introducing an electron-withdrawing p-nitrile (compound 12), or a *p*-borono substitution (compound 13) caused a 1.5-fold improvement in activity, while a p-nitro group (compound 14) caused a 120-fold improvement in activity, yielding an AICAR Tfase inhibitor with a  $K_i$  value of  $685 \pm 35$  nm. Replacing the arginine residue of 14 with lysine (compound 15) resulted in a 75-fold loss of activity.

The effect of N-methylation of the peptide backbone was also explored, as this would be expected to restrict the conformational freedom of the compound, and had been shown to improve the activity of other cyclic peptides.<sup>[13]</sup> N-methylated analogues of the capped RY dimer 8 and its p-nitro analogue 14 were therefore synthesized and assayed. N-methylation of 8 diminished its activity by 1.7-fold, while N-methylation of 14 resulted in a 3.6-fold loss of activity. The observed loss of activity on methylation may be a result of the steric hindrance associated with the methyl group affecting binding to the active site. The p-nitro-tyrosine analogue of cyclo-CRYFNV was also synthesized and assayed to determine if the increase in potency observed for the RY dipeptide upon introduction of *p*-nitro group, would also be observed in the parent cyclic peptide. The p-nitro analogue of cyclo-CRYFNV was found to inhibit AICAR Tfase with a  $K_i$  value of  $36 \pm 4 \,\mu$ M, a surprising twofold reduction in activity compared to the parent compound. Without structural data to identify the binding site of these compounds, the reasons for the observed reduction in activity upon reintroduction of the cyclic peptide backbone remain unclear.

#### Deciphering the mode of action of compound 14

We previously demonstrated by progress rate analysis that cyclo-CRYFNV is a competitive inhibitor of ATIC with respect to 10-f-THF, and that its inhibition of AICAR Tfase is due to disruption of the ATIC dimer.<sup>[8a]</sup> To assess if the most potent dipeptide uncovered in this study maintains this mechanism of action, or inhibits AICAR Tfase through a nonspecific aggregate mechanism,<sup>[14]</sup> **14** was assayed in the presence of **1** and 10 mg mL<sup>-1</sup> of bovine serum albumin (BSA). Inhibition by nonspecific aggregators is prevented by the addition of milligram per milliliter concentrations of BSA (prior to the addition of the enzyme and inhibitor),<sup>[14]</sup> a nonspecific inhibitor would therefore be expected to lose activity under these conditions. The



**Figure 1.** A) The effect of mg mL<sup>-1</sup> quantities of BSA on AICAR Tfase inhibition by **14**. The compound continues to inhibit the enzyme regardless of BSA presence, indicating it does not function through nonspecific aggregation. B) and C) Size-exclusion chromatography. B) The ratio of monomer to dimer is shown in a 50  $\mu$ m solution of ATIC C) The same mixture with 10  $\mu$ m of compound **14** shows the presence of monomeric ATIC at 85 mL.

rate of the AICAR Tfase reaction was not affected by the presence of 1 mg mL<sup>-1</sup> of BSA in the assay buffer, but was slowed by around 40% in the presence of 10 mg mL<sup>-1</sup> BSA (Figure 1 A). This may be due to the high BSA concentration affecting the ATIC monomer–dimer equilibrium by stabilizing the monomeric form of ATIC, and therefore reducing AICAR Tfase activity. In both cases however, compound **14** at 10 and 50  $\mu$ M continued to inhibit the reaction to a similar extent as observed in the absence of BSA (Figure 1 A). This indicated that **14** does not function using a nonspecific aggregate mechanism of inhibition.

To further assess if the inhibition of AICAR Tfase by compound **14** is due to its disruption of ATIC homodimerization, size-exclusion chromatography was utilized. The large change in molecular mass of ATIC upon homodimerization (from 64 kDa to 129 kDa) enables the ratio of monomer to dimer to be monitored by this technique. ATIC has a  $K_d$  value of 240  $\pm$ 50 nm in the absence of its substrates, with a 50 µm solution containing mainly dimeric species.<sup>[15]</sup> Size-exclusion chromatography of a 50 µm solution of ATIC showed a single peak at 72 mL, corresponding to a mass of ~130 kDa (see Figure S17 in the Supporting Information for column calibration), indicating the presence of only dimeric species (Figure 1B).

The experiment was repeated with a 50  $\mu$ M solution of ATIC treated with 10  $\mu$ M of compound **14**. An additional peak at 85 mL was observed, corresponding to a mass of ~65 kDa, indicating the presence of monomeric ATIC (Figure 1 C). As a control, a 50  $\mu$ M solution of ATIC was treated with 10  $\mu$ M of the least potent dipeptide inhibitor identified in this study (compound **9**, Table 2). As **9** is a significantly weaker ATIC inhibitor than **14**, it should not disrupt ATIC dimerization at the concentration used in this experiment. As expected, only a single peak corresponding to dimeric ATIC was observed (Figure S18). The presence of ATIC monomer in the solution treated with **14**, but not in the untreated ATIC solution or that treated with a weak inhibitor, suggests that **14** inhibits AICAR Tfase by perturbing ATIC homodimerization.

#### Inhibition of ATIC homodimerization in breast cancer cells

Inhibition of purine metabolism has been long proposed as a possible approach to targeting tumor growth.<sup>[16]</sup> Two pathways operate in cells for purine production: the purine salvage pathway operates in normal cells, whilst de novo purine production is thought to predominate in rapidly dividing cancer cells. Inhibition of de novo purine biosynthesis has therefore been proposed as a possible strategy for the selective inhibition of growth in rapidly dividing cancer cells. The majority of current inhibitors of enzymes in the de novo purine biosynthetic pathway are folate analogues that inhibit multiple enzymes in the cell; the significance of de novo purine production in cancer therapy is therefore difficult to decipher. We therefore used 14 to assess the effect of inhibiting ATIC dimerization on the viability of a model breast cancer cell line; MCF-7 cells were dosed by addition of 100, 250 or 500 µm of compound 14 to their growth media. The viability of treated versus untreated cells was determined 48 h after dosing, using a nonradioactive proliferation assay. A dose-dependent reduction in viability was observed in cells treated with compound 14 (Figure 2 A), reaching 40% inhibition at the maximum dose of 500 μм. The effect of ATIC inhibition on cell proliferation was further analyzed in cells treated with 250 µm of 14 using timelapse microscopy. Images were captured every 45 min over 72 h and analyzed. These images showed that cells treated with 250  $\mu$ M 14 exhibited a 35% reduction in proliferation compared to control-treated cells (Figure 2B and C). These data were in agreement with that from the cell viability assays (Figure 2A). Further analysis of the videos indicated that the effect of 14 on cell numbers was through a reduction in cell division rates, rather than an increase in cell death. The MCF-7 breast cancer cell line used retains active cell cycle checkpoints that protect from stress-induced cell death,<sup>[17]</sup> which may provide a possible explanation for the above observations. Interestingly, indirect inhibition of AICAR Tfase by the anti-folate methotrexate has been proposed as the principal mode of action for its cytotoxicity in MCF-7 cells.  $\ensuremath{^{\text{[4a]}}}$  Further cell-based studies are necessary to clarify the role of de novo purine biosynthesis in the survival and growth of various cancer cells. Non-folate inhibitors of various enzymes in this pathway, such as compound 14, will be valuable chemical tools for these studies.

In addition to the above, ATIC inhibition has also recently been proposed to be the primary mode of action for the anticancer drug pemetrexed;<sup>[6a]</sup> the rise in unmetabolized AICAR proposed to allosterically activate AMPK by mimicking AMP, causing inhibition of cell proliferation. It is therefore possible that the effect of **14** on cell proliferation is due to AMPK activation, as well as inhibition of de novo purine biosynthesis. This possibility is currently being investigated in our laboratory.

#### Conclusions

The development of a small-molecule inhibitor of ATIC homodimerization with a  $K_i$  value of 685 nm from a cyclic hexapeptide is reported. The finding that four of the six amino acids of cyclo-CRYFNV can be eliminated, and that the RY dipeptide is sufficient to disrupt the interaction of a 5000 Å<sup>2</sup> interface raises several interesting questions about the possible binding site of the compound, and may be significant for the peptidomimetic evolution of other cyclic peptide inhibitors of protein–protein interactions.<sup>[18]</sup>

We are currently developing nonpeptidic analogues of 14 with the aim of further improving the potency of this compound. Structural studies are also underway to determine the binding pocket targeted on ATIC, and to enable further optimization of the inhibitor using traditional medicinal chemistry approaches. Experiments are also underway to decipher the mechanism by which 14 inhibits cell proliferation and to determine the effect of 14 on the proliferation of other cancer cell lines and in vivo tumor models. Whilst the potency of 14 may be further improved as a result of these efforts, the compound is sufficiently active in its current form to serve as a tool for

1631



**Figure 2.** Assessing the proliferation of MCF-7 cells treated with **14**. A) MTS assays show a dose-dependent reduction in viable cells 48 h after treatment. B) Analysis of cell growth by live-cell imaging. C) Representative images from live-cell imaging showing a population of untreated cells over 72 h, compared to a population of cells treated with **14**. The reduction in proliferation in cells treated with **14** is due to reduced rate of division rather than increased cell death.

investigations into the role of de novo purine biosynthesis in cells.

### **Experimental Section**

General: Amino acids and peptide coupling reagents were obtained from Merck (Novabiochem). All other chemical reagents were obtained from Sigma-Aldrich or Fisher Scientific and used without further purification. Thin-layer chromatography (TLC) was carried out on Merck silica gel plates with a fluorescence indicator (254 nm). Visualization of TLC plates was carried out by UV light, then by using either a cerium sulfate/ammonium molybdate or potassium permanganate stain. Flash chromatography was performed with 35-70 µm silica gel (Fisher Davisil). Infrared spectra were recorded using a FTIR spectrometer fitted with an attenuated total reflectance (ATR) accessory. <sup>1</sup>H NMR and <sup>13</sup>C NMR were recorded using a Bruker DPX400 (400 and 100 MHz respectively). Chemical shifts ( $\delta$ ) are given in ppm. All enzymatic assays were performed using a Varian Cary 100 Spectrometer. All peptides were purified on a Waters HPLC instrument, using a Waters Atlantis Prep T3 OBD 5 um 19×100 mm column using a water/acetonitrile mix at a flow rate of 17 mLmin<sup>-1</sup>. For cell culture experiments, all reagents were obtained from Invitrogen. MCF-7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Autogen Bioclear), penicillin (100 UmL<sup>-1</sup>), streptomycin (100  $\mu$ g mL<sup>-1</sup>), and L-glutamine (292  $\mu$ g mL<sup>-1</sup>).

**Cyclic peptide synthesis:** The alanine-scanning analogues of CRYFNV were synthesized and purified as previously described for CRYFNV.<sup>[8a]</sup>

**Synthesis of capped dipeptides:** The dipeptides in Table 2 were synthesized as outlined for compound **8** in Scheme 3 on a 500 mg scale. Further experimental details and analytical information for compounds **8–13** and **15–17** are provided as Supporting Information. The synthesis of compound **14** is detailed below:

Synthesis of Boc-Phe(4-NO2)-diethylamide: Dry CH2Cl2 (8 mL) and Boc-4-nitro-L-phenylalanine (500 mg, 1.61 mmol) were added to a three-neck flask under an inert atmosphere, with vigorous stirring. To this mixture, EDC hydrochloride (309 mg, 1.61 mmol) and HOBt (218 mg, 1.61 mmol) were added, and the solution was stirred for 30 min at room temperature. Diethylamine (0.34 mL, 3.38 mmol) was added and the resulting yellow solution was left to stir for 4 h. The progress of this reaction was checked by TLC, and was shown to be complete in 4 h. The reaction was stopped, diluted with CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and washed with citric acid (10 mL), NaHCO<sub>3</sub> saturated solution (10 mL) and brine (10 mL). The organic phase was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated in vacuo to give a pale yellow oil that solidified upon standing. The crude material was dried under an argon stream and reprecipitated using cold hexane to give a white solid that was collected in a Buchner funnel (483 mg, 82% yield).  $R_{\rm f}$ =0.82 (EtOAc/Hex 2:1). m.p. 90–90.5 °C. <sup>1</sup>H NMR (300 MHz, [D<sub>6</sub>]DMSO):  $\delta = 8.17$  (d, J =8.8 Hz, 2H, Ar), 7.57 (d, J=8.8 Hz, 2H, Ar), 7.31 (d, J=8.4 Hz, 1H, NH), 4.57 (q, J=7.7 Hz, 1H, CH<sub>2</sub>); 2.97-3.41 (m, 6H, CH), 1.30 (s, 9H, tBu), 1.08 (t, J=6.9 Hz, 3H, CH<sub>3</sub>), 1.01 ppm (t, J=6.9 Hz, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (75 MHz, [D<sub>6</sub>]DMSO):  $\delta$  = 169.7, 154.9, 146.3, 130.8, 123.7, 78.1, 51.1, 41.1, 37.5, 27.9, 14.2, 12.7 ppm; HRMS/ES<sup>+</sup> (*m/z*): calcd for C<sub>18</sub>H<sub>27</sub>N<sub>3</sub>O<sub>5</sub>Na: 388.1843 [*M*+Na]<sup>+</sup>; found: 388.1854  $[M+Na]^+$ .

Synthesis of Fmoc-Arg(Pbf)-CONH-Phe(4-NO<sub>2</sub>)-L-diethylamide: Dry  $CH_2Cl_2$  (6 mL) and Boc-4-nitro-L-phenyldiethylamide (350 mg, 1.32 mmol) were added to a flask under an inert atmosphere with

© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

ChemBioChem 2012, 13, 1628-1634

vigorous stirring. Trifluoracetic acid (6 mL) was added to this mixture and stirred for 1 h. The reaction was monitored by TLC. After this time, the solvent was removed in vacuo and the orange oil coevaporated with EtOAc (3×10 mL) to give a yellow oil (350 mg, 100% yield) whose identity was confirmed by mass spectrometry. The deprotected amine was added to stirred dry CH<sub>2</sub>Cl<sub>2</sub> (15 mL) in a flask under an inert atmosphere. Fmoc-Arg(Pbf)-OH (1.88 mg, 3.0 mmol) was added to this solution and the reaction was cooled to -20°C. HOBt (535 mg, 3.96 mmol) and EDC (380 mg, 1.98 mmol) were added, and the reaction was left to stir overnight and allowed equilibrate to room temperature. The reaction was diluted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL), washed with citric acid (20 mL), saturated NaHCO<sub>3</sub> solution (20 mL) and brine (20 mL). The yellow solution was evaporated in vacuo to leave a yellow solid, which was purified using column chromatography with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (95:5) to give the product ( $R_f = 0.45$ ) as an off-white solid (520 mg, 44%) yield). m.p. 110 °C decomp. <sup>1</sup>H NMR (300 MHz, [D<sub>6</sub>]DMSO):  $\delta$  = 8.25 (d, J=8.4 Hz, 1 H), 8.03 (d, J=8.4 Hz, 2 H), 7.84 (d, J=7.3 Hz, 2 H), 7.65 (d, J=8.8 Hz, 2 H), 7.46-7.34 (m, 7 H), 4.96-4.89 (m, 1 H), 4.34-4.22 (m, 3H), 4.04-4.00 (m, 1H), 3.35-2.98 (m, 12H), 2.47 (s, 3H), 2.04 (s, 3 H), 1.43 (brs, 10 H), 1.07–0.97 ppm (m, 6 H); <sup>13</sup>C NMR (75 MHz, [D<sub>6</sub>]DMSO):  $\delta = 172.3$ , 170.1, 158.4, 157.0, 156.7, 147.2, 146.6, 144.8, 144.6, 141.7, 138.2, 132.4, 131.7, 131.6, 128.6, 128.0, 126.1, 125.2, 124.0, 123.9, 121.0, 117.2, 87.2, 66.5, 60.7, 55.1, 50.3, 47.6, 43.4, 42.1, 38.6, 29.2, 19.9, 18.5, 15.2, 13.7, 13.2 ppm; LRMS/ ES<sup>+</sup> (*m/z*): 896 [*M*+H]<sup>+</sup> 5%, 918 [*M*+Na]<sup>+</sup> 100%, 1813 [2*M* < M + > Na]<sup>+</sup> 9.6%. HRMS/ES<sup>+</sup> (*m/z*): calcd for C<sub>47</sub>H<sub>58</sub>N<sub>7</sub>O<sub>9</sub>S: 896.4011 [*M*+H]<sup>+</sup>; found: 896.4010 [*M*+H]<sup>+</sup>.

Synthesis of amino-Arg(Pbf)-CONH-Phe(4-NO<sub>2</sub>)-L-diethylamide: Dry EtOAc (14 mL) was added to Fmoc-Arg(Pbf)-CONH-Phe(4-NO<sub>2</sub>)diethylamide (520 mg, 0.58 mmol) in a flask under an inert atmosphere and stirred vigorously. To this mixture, DBU (93 mg, 0.1 mL, 0.61 mmol) was added; the solution was stirred for 1 h, and the reaction was monitored using TLC. The solvent was removed in vacuo to give a brown solid, which was purified using column chromatography with  $CH_2Cl_2/MeOH$  (9:1) to give the product ( $R_f =$ 0.35) as a white solid (363 mg, 93% yield). m.p. 121  $^\circ\text{C}$  decomp. <sup>1</sup>H NMR (300 MHz, [D<sub>6</sub>]DMSO):  $\delta = 8.31$  (d, J = 8.4 Hz, 1 H), 8.15 (d, J=8.4 Hz, 2 H), 7.51 (d, J=7.3 Hz, 2 H), 4.96-4.91 (m, 1 H), 3.43-2.94 (m, 13 H), 2.54–2.46 (m, 8 H overlap [D<sub>6</sub>]DMSO), 2.03 (s br, 5 H), 1.44 (s br, 10 H), 1.07–0.97 ppm (m, 6 H); <sup>13</sup>C NMR (75 MHz, [D<sub>6</sub>]DMSO):  $\delta\!=\!174.3,\ 169.3,\ 157.3,\ 156.0,\ 146.2,\ 145.7,\ 137.2,\ 134.2,\ 131.3,$ 130.7, 124.2, 123.0, 116.2, 86.2, 54.1, 48.7, 42.4, 41.1, 37.9, 32.1, 28.2, 25.3, 18.9, 17.5, 14.3, 12.7, 12.2 ppm; LRMS/ES<sup>+</sup> (m/z): 674  $[M+H]^+$  39%, 696  $[M+Na]^+$  100%, 1869  $[2M < M + > Na]^+$  11%. HRMS/ES<sup>+</sup> (*m*/*z*): calcd for  $C_{32}H_{47}N_7O_7S$ : 674.3330 [*M*+H]<sup>+</sup>; found: 674.3319 [*M*+H]<sup>+</sup>.

Synthesis of acetyl-Arg(Pbf)-CONH-Phe(4-NO<sub>2</sub>)-L-diethylamide: Dry ethyl acetate (7 mL) and Fmoc-Arg(Pbf)-CONH-Phe(4-NO<sub>2</sub>)-diethylamide (363 mg, 0.54 mmol) were added to flask under an inert atmosphere and stirred vigorously. Triethylamine (58 mg, 0.08 mL, 0.57 mmol), and acetic anhydride (58 mg, 0.05 mL, 0.57 mmol) were added to this mixture and stirred overnight. The solvent was removed in vacuo giving a sticky yellow oil that was purified by column chromatography (short path) using CH<sub>2</sub>Cl<sub>2</sub>/ MeOH 9:1 to give a white solid ( $R_f$ =0.52) in quantitative yield (386 mg, 100% yield). m.p. 113 °C decomp. <sup>1</sup>H NMR (300 MHz, [D<sub>6</sub>]DMSO):  $\delta$ =8.36 (d, J=8.4 Hz, 1 H), 8.14 (d, J=8.8 Hz, 2 H), 7.89 (d, J=8.2 Hz, 2 H), 7.56 (d, 8.8 Hz, 2 H), 4.92–4.84 (m, 1 H), 4.28–4.24 (m, 1 H), 3.36–2.99 (m, 16 H), 2.54–2.51 (s br, 8 H overlap [D<sub>6</sub>]DMSO), 2.45 (s, 3 H), 1.94 (s, 3 H), 1.84 (s, 3 H), 1.55–1.28 (brs, 11 H), 1.05– 0.96 ppm (m, 6H); <sup>13</sup>C NMR (75 MHz, [D<sub>6</sub>]DMSO):  $\delta$ =172.1, 170.1, 168.9, 157.3, 155.9, 147.1, 146.7, 138.1, 135.1, 135.1, 133.3, 131.7, 125.2, 124.0, 117.1, 87.2, 50.3, 43.4, 42.0, 38.5, 30.4, 29.1, 26.3, 23.3, 22.0, 18.5, 15.2, 13.6, 13.2 ppm; LRMS/ES<sup>+</sup> (*m/z*): 716  $[M+H]^+$  100%, 1431  $[2M+Na]^+$  26%; HRMS/ES<sup>+</sup> (*m/z*): calcd for C<sub>34</sub>H<sub>50</sub>N<sub>7</sub>O<sub>8</sub>S: 716.3436  $[M+H]^+$ ; found: 716.3434  $[M+H]^+$ .

Synthesis of acetyl-Arg-CONH-Phe(4-NO<sub>2</sub>)-L-diethylamide: To a flask, a cocktail of TFA/TIS/H<sub>2</sub>O (9.5:0.25:0.25, 22 mL) and acetyl-Arg(Pbf)-CONH-Phe(4-NO<sub>2</sub>)-diethylamide (386 mg, 0.54 mmol) were added, and stirred at room temperature for 2 h. The reaction was monitored by TLC, and the solvent evaporated in vacuo to leave a viscous yellow oil. This was co-evaporated with CH<sub>2</sub>Cl<sub>2</sub> (3×5 mL) and MeOH (3×5 mL) and the residue dried with an argon stream for ~20 min. Diethyl ether (20 mL) was then added and the white precipitate collected by filtration (263 mg, 100% crude yield). The crude product was purified by reversed-phase HPLC ( $t_{\rm R}$  = 7.63 min) and lyophilized to obtain the product as a white solid (125 mg, 50% yield). m.p. 113 °C decomp. <sup>1</sup>H NMR (300 MHz, [D<sub>6</sub>]DMSO):  $\delta =$ 8.31 (d, J=8.7 Hz, 1 H), 8.10 (d, J=8.6 Hz, 2 H), 7.91 (d, J=8.1 Hz, 2H), 7.65 (t, J=5.6 Hz, 1H), 7.50 (d, 8.6 Hz, 2H), 7.17 (brs, 3H), 4.90-4.82 (m, 1 H), 4.32-4.23 (m, 1 H), 3.37-3.00 (m, 7 H), 2.95 (dd, 1 H), 1.82 (s, 3 H), 1.61-1.50 (m, 3 H), 1.00 (t, 7.12 Hz, 3 H), 0.95 ppm (t, 7.13 Hz, 6 H);  ${}^{13}$ C NMR (75 MHz, [D<sub>6</sub>]DMSO):  $\delta = 171.1,169.1$ , 169.1, 156.8, 146.3, 145.8, 130.8, 123.1, 51.8, 49.4, 41.4, 40.4, 39.8, 37.6, 29.2, 25.0, 22.4, 14.2, 12.7 ppm; LRMS/ES<sup>+</sup> (*m*/*z*): 464 [*M*+H]<sup>+</sup> 100%; HRMS/ES<sup>+</sup> (*m*/*z*): calcd for  $C_{21}H_{33}N_7O_5$ : 464.2616 [*M*+H]<sup>+</sup>; found: 464.2610 [*M*+H]<sup>+</sup>.

**Protein expression and enzyme kinetics:** Avian and human ATIC fused to an N-terminal His<sub>6</sub> tag were expressed from pET28 vectors in BL21(DE3) strains of *Escherichia coli*, and purified as previously described.<sup>[8a, 19]</sup> AICAR Tfase assays were conducted with avian ATIC and carried out in 1 cm path length quartz cuvettes at 25 °C as previously described.<sup>[8a, 19]</sup> Each inhibitor was dissolved in DMSO to give a 100 mM stock solution that was further diluted for use in each assay. The data was analyzed using KaleidaGraph (Synergy Software) and Microsoft Excel, by assuming competitive inhibition with 10-f-THF as previously described.<sup>[8a]</sup> Errors in the  $K_i$  values were calculated by linear regression. Compounds **1**, **8**, and **14** were also assayed with human ATIC, with the same  $K_i$  value (within error) being observed for each compound as for the avian enzyme.

**Size-exclusion chromatography:** Three 50  $\mu$ M solutions of human ATIC were prepared as above, in buffer [20 mM Tris-HCl, pH 7.5, NaCl (150 mM), KCl (50 mM), EDTA (5 mM), dithiothreitol (5 mM), 1 mL]. Compound **14** or **9** (negative control; 10  $\mu$ M) was added to two of these solutions. Each solution was filtered through a Millex GP 0.22  $\mu$ m filter (Millipore), and loaded onto a HiLoad 16/60 Superdex 200 gel filtration column (GE Healthcare) pre-equilibrated with the above buffer. The flow rate was 1 mLmin<sup>-1</sup> and the flow monitored by UV absorbance on an AKTAprime FPLC instrument (GE Healthcare). The column was calibrated using a HMW gel filtration calibration kit (GE Healthcare).

**Cell proliferation assays:** Cells were plated at 2000 cells per well in 96-well plates 24 h prior to dosing with appropriate drug in fresh medium (100  $\mu$ L); the final concentration of solvent DMSO in each well was 0.5%. MTS-based cell proliferation assays were performed 48 h post-dosing according to the manufacturer's instructions (CellTitre Aqueous One Cell Proliferation assay, Promega).

**Live-cell imaging:** Cells were plated at 10000 cells per well in 24well plates. Time-lapse microscopy<sup>[17]</sup> was initiated on dosing, with images captured every 45 min for 72 h. Analysis was carried out using Image J software. All conditions were assayed in triplicate, and expressed as means  $\pm$  S.E.M. Statistical significance was calcu-

# **CHEMBIO**CHEM

lated using the one-way ANOVA parametric test and Tukey's post hoc test using Prism software (GraphPad).

#### Acknowledgements

We thank Dr. Josephine Corsi, Dr. Peter Roach, and Dr. Michael Webb for helpful discussions, and Abigail Male for the SEC calibration data. This work was funded by National Institutes of Health grant GM24129-28, and Cancer Research UK grant 10263.

**Keywords:** AICAR transformylase · ATIC · cancer · peptides · protein–protein interaction inhibitors

- D. Cardinale, O. M. Salo-Ahen, S. Ferrari, G. Ponterini, G. Cruciani, E. Carosati, A. M. Tochowicz, S. Mangani, R. C. Wade, M. P. Costi, *Curr. Med. Chem.* 2010, *17*, 826–846.
- [2] L. Ni, K. Guan, H. Zalkin, J. E. Dixon, Gene 1991, 106, 197-205.
- [3] S. E. Greasley, P. Horton, J. Ramcharan, G. P. Beardsley, S. J. Benkovic, I. A. Wilson, Nat. Struct. Biol. 2001, 8, 402–406.
- [4] a) C. J. Allegra, K. Hoang, G. C. Yeh, J. C. Drake, J. Baram, J. Biol. Chem. 1987, 262, 13520–13526; b) J. L. Bronder, R. G. Moran, Cancer Res. 2002, 62, 5236–5241.
- [5] a) Y. Zhang, J. Desharnais, T. H. Marsilje, C. Li, M. P. Hedrick, L. T. Gooljarsingh, A. Tavassoli, S. J. Benkovic, A. J. Olson, D. L. Boger, I. A. Wilson, *Biochemistry* 2003, 42, 6043–6056; b) T. H. Marsilje, M. A. Labroli, M. P. Hedrick, Q. Jin, J. Desharnais, S. J. Baker, L. T. Gooljarsingh, J. Ramcharan, A. Tavassoli, Y. Zhang, I. A. Wilson, G. P. Beardsley, S. J. Benkovic, D. L. Boger, *Bioorg. Med. Chem.* 2002, 10, 2739–2749; c) J. Desharnais, I. Hwang, Y. Zhang, A. Tavassoli, J. Baboval, S. J. Benkovic, I. A. Wilson, D. L. Boger, *Bioorg. Med. Chem.* 2003, 11, 4511–4521; d) T. H. Marsilje, M. P. Hedrick, J. Desharnais, A. Tavassoli, Y. Zhang, I. A. Wilson, S. J. Benkovic, D. L. Boger, *Bioorg. Med. Chem.* 2003, 11, 4511–4521; d) T. H. Marsilje, M. P. Hedrick, J. Desharnais, A. Tavassoli, Y. Zhang, I. A. Wilson, S. J. Benkovic, D. L. Boger, *Bioorg. Med. Chem.* 2003, 11, 4487–4501.
- [6] a) A. C. Racanelli, S. B. Rothbart, C. L. Heyer, R. G. Moran, *Cancer Res.* 2009, 69, 5467–5474; b) S. B. Rothbart, A. C. Racanelli, R. G. Moran, *Cancer Res.* 2010, 70, 10299–10309.

- [7] R. I. Christopherson, S. D. Lyons, P. K. Wilson, Acc. Chem. Res. 2002, 35,
- [8] a) A. Tavassoli, S. J. Benkovic, Angew. Chem. 2005, 117, 2820-2823;
  Angew. Chem. Int. Ed. 2005, 44, 2760-2763; b) K. J. Capps, J. Humiston,
  R. Dominique, I. Hwang, D. L. Boger, Bioorg. Med. Chem. Lett. 2005, 15, 2840-2844.
- [9] A. Tavassoli, S. J. Benkovic, Nat. Protoc. 2007, 2, 1126-1133.

961-971.

- [10] R. M. Liskamp, D. T. Rijkers, J. A. Kruijtzer, J. Kemmink, ChemBioChem 2011, 12, 1626–1653.
- [11] K. G. Bulock, G. P. Beardsley, K. S. Anderson, J. Biol. Chem. 2002, 277, 22168–22174.
- [12] C. P. Scott, E. Abel-Santos, M. Wall, D. C. Wahnon, S. J. Benkovic, Proc. Natl. Acad. Sci. USA 1999, 96, 13638–13643.
- [13] J. Chatterjee, C. Gilon, A. Hoffman, H. Kessler, Acc. Chem. Res. 2008, 41, 1331–1342.
- [14] a) K. E. Coan, B. K. Shoichet, *Mol. Biosyst.* 2007, *3*, 208–213; b) S. L. Mc-Govern, E. Caselli, N. Grigorieff, B. K. Shoichet, *J. Med. Chem.* 2002, *45*, 1712–1722.
- [15] J. M. Vergis, K. G. Bulock, K. G. Fleming, G. P. Beardsley, J. Biol. Chem. 2001, 276, 7727 – 7733.
- [16] a) Y. M. Rustum, H. Takita, G. Gomez, Antibiot. Chemother. 1980, 28, 86– 93; b) G. Weber, M. Nagai, Y. Natsumeda, S. Ichikawa, H. Nakamura, J. N. Eble, H. N. Jayaram, W. N. Zhen, E. Paulik, R. Hoffman, G. Tricot, Adv. Enzyme Regul. 1991, 31, 45–67; c) Y. Natsumeda, N. Prajda, J. P. Donohue, J. L. Glover, G. Weber, Cancer Res. 1984, 44, 2475–2479; d) Y. M. Marijnen, D. de Korte, W. A. Haverkort, E. J. den Breejen, A. H. van Gennip, D. Roos, Biochim. Biophys. Acta Mol. Cell Res. 1989, 1012, 148–155.
- [17] L. M. Bergman, C. N. Birts, M. Darley, B. Gabrielli, J. P. Blaydes, *Mol. Cell Biol.* 2009, *29*, 4539–4551.
- [18] A. Tavassoli, Q. Lu, J. Gam, H. Pan, S. J. Benkovic, S. N. Cohen, ACS Chem. Biol. 2008, 3, 757–764.
- [19] M. Wall, J. H. Shim, S. J. Benkovic, Biochemistry 2000, 39, 11303-11311.

Received: April 25, 2012 Published online on July 4, 2012